DEF: Acurx Pharmaceuticals Seeks Shareholder Approval for Reverse Stock Split and Major Capital Raises to Maintain Nasdaq Listing and Fund Operations

Acurx Pharmaceuticals, Inc. is calling its 2025 Annual Meeting to approve a reverse stock split to regain Nasdaq compliance, authorize significant share issuances for capital, and expand its equity incentive plan.

Summary

• Acurx Pharmaceuticals, Inc. will hold its 2025 Annual Meeting virtually on Thursday, July 17, 2025, at 10:00 a.m. EST.
• Shareholders will vote on the election of two Class I directors to serve three-year terms expiring in 2028.
• A proposal to ratify CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, will be presented.
• The company seeks approval for an amendment to its certificate of incorporation to effect a reverse stock split at a ratio of not less than 1:10 and not more than 1:30, aimed at increasing the stock price to meet Nasdaq's minimum bid price requirement.
• Shareholder approval is requested for the issuance of 8,399,700 shares of common stock underlying Series F Warrants and warrants issued to H.C. Wainwright & Co. LLC, to comply with Nasdaq Listing Rule 5635(d). These warrants have exercise prices of $0.40 and $0.50 per share, respectively, potentially generating approximately $3.4 million in gross proceeds upon exercise.
• Approval is also sought for the issuance of shares of common stock to Lincoln Park Capital Fund, LLC, under a purchase agreement dated May 8, 2025, for up to $12.0 million, also to comply with Nasdaq Listing Rule 5635(d) as it exceeds 19.99% of outstanding common stock. The company has already issued 899,258 commitment shares to Lincoln Park.
• An amendment to the 2021 Equity Incentive Plan is proposed to increase the number of shares available for sale from 177,448 to 2,677,448, which would increase the equity overhang from 14% to 21%.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative. While the company is taking necessary steps to address critical issues like Nasdaq compliance and capital funding, the underlying need for a reverse stock split due to low share price and the substantial potential dilution from the proposed capital raises indicate significant financial challenges and a precarious market position. The proposals are reactive to adverse conditions rather than indicative of strong operational performance.

Positives

• The company is proactively addressing its Nasdaq minimum bid price deficiency by proposing a reverse stock split.
• The proposed warrant exercises and the purchase agreement with Lincoln Park Capital Fund, LLC provide avenues for significant capital infusion, crucial for funding operations, clinical trials, and product development.
• The increase in the 2021 Equity Incentive Plan shares aims to enhance the company's ability to attract, retain, and motivate key employees and directors.

Negatives

• The company is currently non-compliant with Nasdaq's minimum bid price requirement, having received a notice on February 24, 2025, and faces potential delisting if compliance is not regained by August 25, 2025.
• The proposed capital raises through warrant exercises and the Lincoln Park agreement will result in significant dilution for existing shareholders.
• There is no assurance that the reverse stock split will result in a permanent increase in the market price of the common stock or that the company will maintain its Nasdaq listing.
• The liquidity of the common stock may be harmed by the reduced number of shares outstanding after a reverse stock split.
• Failure to obtain stockholder approval for the warrant exercise proposal could lead to substantial additional costs from holding multiple special meetings and adversely impact the company's ability to fund operations.

Risks

• The reverse stock split may not result in a sustained increase in the market price of the common stock, and the total market capitalization may be lower after the split.
• The liquidity of the common stock could be adversely affected by the reduced number of shares outstanding post-reverse split.
• The reverse stock split may increase the number of stockholders holding 'odd lots' (less than 100 shares), potentially increasing their selling costs and difficulty in effecting sales.
• The significant issuance of shares upon exercise of warrants and under the Lincoln Park agreement will cause substantial dilution to existing stockholders' ownership interests and voting power.
• The sale of shares into the public market by Lincoln Park Capital Fund, LLC could materially and adversely affect the market price of the common stock.
• If stockholder approval for the ELOC Issuance Proposal is not obtained, the company may be unable to fully utilize the $12.0 million available under the Purchase Agreement, potentially hindering its ability to fund business plans and impacting future operating results.

Future Outlook

The company's future outlook is focused on regaining Nasdaq compliance through a reverse stock split and securing substantial capital through warrant exercises and a purchase agreement with Lincoln Park Capital Fund, LLC. These funds are intended to support ongoing operations, advance clinical trials, and develop and commercialize product candidates. The ability to fully utilize the Lincoln Park agreement is contingent on shareholder approval, which is critical for the company's anticipated funding needs.

Management Comments

• "Thank you for your continued support of Acurx. We look forward to seeing you at the Annual Meeting." David P. Luci, President & Chief Executive Officer.
• The board of directors unanimously recommends the approval of all proposals presented at the Annual Meeting.

Industry Context

Acurx Pharmaceuticals operates in the biopharmaceutical industry, which is highly capital-intensive, particularly for companies engaged in drug development and clinical trials. The need for significant capital raises, as evidenced by the warrant issuances and the Lincoln Park agreement, is typical for biotech firms at various stages of development. Maintaining a Nasdaq listing is crucial for such companies to ensure liquidity for their stock, attract institutional investors, and facilitate future capital access. Reverse stock splits are a common measure taken by companies, especially in the biotech sector, to meet exchange listing requirements when their share price falls below minimum thresholds, reflecting the inherent volatility and risk associated with early-stage or development-stage pharmaceutical companies.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The Audit Committee considered the status of pending litigation as part of its oversight relating to the financial reporting and audit process.

Related Party Transactions

• The company has entered into indemnification agreements with each of its directors and executive officers, providing for indemnification against expenses, judgments, fines, and penalties.
• On January 6, 2025, David P. Luci (President and CEO), Robert J. DeLuccia (Executive Chairman), Carl V. Sailer, Jack H. Dean, James Donohue, and Joseph Scodari (directors) participated in a registered direct offering and concurrent private placement, purchasing an aggregate of 167,488 shares of common stock and affiliate warrants at an exercise price of $0.90 per share.

Stakeholder Impact

• **Shareholders**: Will experience significant dilution from the issuance of shares underlying warrants and the Lincoln Park Capital Fund agreement. The reverse stock split aims to maintain Nasdaq listing, which could benefit shareholders by preserving liquidity and institutional investor interest, but there's a risk it may not sustain the stock price. Shareholders will receive cash in lieu of fractional shares from the reverse split.
• **Employees, Directors, and Consultants**: The proposed increase in the 2021 Equity Incentive Plan shares will provide more opportunities for equity-based compensation, which can aid in talent attraction and retention.
• **Company Operations**: The capital raised through the warrant exercises and the Lincoln Park agreement is crucial for funding the company's ongoing operations, advancing clinical trials, and developing and commercializing product candidates, directly impacting the company's ability to execute its business strategy.
• **Creditors**: The capital raises could improve the company's financial stability, potentially reducing credit risk, though the terms of the capital raises (e.g., dilution) could also be a factor in their assessment.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on July 17, 2025, to vote on the proposed corporate actions.
• If the reverse stock split proposal is approved, the board of directors will determine the exact ratio (between 1:10 and 1:30) and the timing of its implementation.
• If the Warrant Exercise Proposal is not approved, the company is obligated to hold additional stockholder meetings every 60 days until approval is obtained or the warrants are no longer outstanding.
• The company will continue efforts to keep the registration statement for the resale of shares underlying the warrants effective.
• The company may, at its sole discretion, direct Lincoln Park Capital Fund, LLC to purchase shares of common stock under the Purchase Agreement over the next 24 months, subject to certain conditions and limitations.
• The company will publish preliminary or final voting results in a Current Report on Form 8-K within four business days of the Annual Meeting.

Key Dates

Recommendation

Keywords

Acurx Pharmaceuticals, ACXP, Proxy Statement, Reverse Stock Split, Nasdaq Listing, Capital Raise, Equity Incentive Plan, Warrants, Lincoln Park Capital, Biopharmaceutical, Corporate Governance, Shareholder Meeting, Dilution